Oppenheimer Reiterates an 'Outperform' on Curis (CRIS) After Management Reaffirms Story and Pipeline

June 18, 2012 9:53 AM EDT Send to a Friend
Get Alerts CRIS Hot Sheet
Price: $3.89 -0.51%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 24
Trade CRIS Now!
Oppenheimer reiterates an 'Outperform' on Curis (NASDAQ: CRIS) price target of $7.50.

Analyst, Boris Peaker, said, "The meeting reaffirmed our confidence in the commercial potential of Erivedge. Consistent with our prior comments, we do not see any near-term competitors to Erivedge. This is important not only from a direct competitive perspective, but also because the royalty agreement between Roche and Curis includes a provision for royalty rate reduction in case of a competitor launch for the same indication. Curis's wholly owned pipeline assets (CUDC-101 and CUDC-907) showed encouraging initial data, but in our view it is too early to model these assets individually."

For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.

Shares of Curis closed at $4.75 yesterday, with a 52 week range of $2.70-$5.65.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments

Add Your Comment